From Nasdaq: 2025-05-14 02:23:00

GSK plc has agreed to acquire Boston Pharmaceuticals’ BP Asset IX Inc. for $2 billion, with $1.2 billion upfront and up to $800 million in milestone payments. This includes responsibility for payments to Novartis Pharma AG for efimosfermin, a potential treatment for steatotic liver disease. GSK will pay $1.2 billion upfront, with the potential for an additional $800 million in milestone payments. The deal will be treated as a business combination and is subject to regulatory approvals under the Hart-Scott-Rodino Act in the US.



Read more at Nasdaq: GSK Acquires BP Asset IX Inc. For $2 Bln To Advance Efimosfermin In SLD Treatment